Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Biomark Diagnostics

DB:20B
Snowflake Description

Mediocre balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
20B
DB
€7M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Biomark Diagnostics has significant price volatility in the past 3 months.
20B Share Price and Events
7 Day Returns
-23.4%
DB:20B
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
263%
DB:20B
-13.2%
DE Biotechs
-20.9%
DE Market
20B Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biomark Diagnostics (20B) -23.4% -8.4% -42.4% 263% 92.2% -68.2%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 20B outperformed the Biotechs industry which returned -13.2% over the past year.
  • 20B outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
20B
Industry
5yr Volatility vs Market

20B Value

 Is Biomark Diagnostics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biomark Diagnostics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biomark Diagnostics.

DB:20B Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 6%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:20B
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 26.5%) (8.75%))
1.177
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.18
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.177 * 5.44%)
6.01%

Discounted Cash Flow Calculation for DB:20B using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biomark Diagnostics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:20B DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 6.01%)
2020 0.39 Est @ 96.43% 0.37
2021 0.65 Est @ 67.39% 0.58
2022 0.96 Est @ 47.05% 0.81
2023 1.28 Est @ 32.82% 1.01
2024 1.57 Est @ 22.86% 1.17
2025 1.82 Est @ 15.88% 1.28
2026 2.02 Est @ 11% 1.34
2027 2.17 Est @ 7.58% 1.36
2028 2.28 Est @ 5.19% 1.35
2029 2.36 Est @ 3.52% 1.32
Present value of next 10 years cash flows CA$10.00
DB:20B DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CA$2.36 × (1 + -0.39%) ÷ (6.01% – -0.39%)
CA$36.72
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$36.72 ÷ (1 + 6.01%)10
CA$20.48
DB:20B Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$10.00 + CA$20.48
CA$30.48
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$30.48 / 72.31
CA$0.42
DB:20B Discount to Share Price
Calculation Result
Exchange Rate CAD/EUR
(Reporting currency to currency of DB:20B)
0.656
Value per Share
(EUR)
= Value per Share in CAD x Exchange Rate (CAD/EUR)
= CA$0.42 x 0.656
€0.28
Value per share (EUR) From above. €0.28
Current discount Discount to share price of €0.10
= -1 x (€0.10 - €0.28) / €0.28
64.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Biomark Diagnostics is available for.
Intrinsic value
>50%
Share price is €0.098 vs Future cash flow value of €0.27644
Current Discount Checks
For Biomark Diagnostics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Biomark Diagnostics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Biomark Diagnostics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biomark Diagnostics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biomark Diagnostics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:20B PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CAD CA$-0.02
DB:20B Share Price ** DB (2020-04-03) in EUR €0.1
DB:20B Share Price converted to CAD reporting currency Exchange rate (EUR/ CAD) 1.525 CA$0.15
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biomark Diagnostics.

DB:20B PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:20B Share Price ÷ EPS (both in CAD)

= 0.15 ÷ -0.02

-9.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biomark Diagnostics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Biomark Diagnostics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Biomark Diagnostics's expected growth come at a high price?
Raw Data
DB:20B PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biomark Diagnostics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biomark Diagnostics's assets?
Raw Data
DB:20B PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CAD CA$0.00
DB:20B Share Price * DB (2020-04-03) in EUR €0.1
DB:20B Share Price converted to CAD reporting currency Exchange rate (EUR/ CAD) 1.525 CA$0.15
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:20B PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:20B Share Price ÷ Book Value per Share (both in CAD)

= 0.15 ÷ 0.00

-33.2x

* Primary Listing of Biomark Diagnostics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biomark Diagnostics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Biomark Diagnostics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biomark Diagnostics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

20B Future Performance

 How is Biomark Diagnostics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomark Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biomark Diagnostics expected to grow at an attractive rate?
  • Unable to compare Biomark Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Biomark Diagnostics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Biomark Diagnostics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:20B Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:20B Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:20B Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 0 -1
2019-09-30 0 -1
2019-06-30 0 -1
2019-03-31 0 -1
2018-12-31 -1 -1
2018-09-30 -1 -1
2018-06-30 -1 -1
2018-03-31 -1 -1
2017-12-31 0 -1
2017-09-30 0 -1
2017-06-30 0 -1
2017-03-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Biomark Diagnostics is high growth as no earnings estimate data is available.
  • Unable to determine if Biomark Diagnostics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:20B Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Biomark Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:20B Past Financials Data
Date (Data in CAD Millions) EPS *
2019-12-31 -0.02
2019-09-30 -0.01
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biomark Diagnostics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 20B’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Biomark Diagnostics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Biomark Diagnostics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Biomark Diagnostics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biomark Diagnostics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

20B Past Performance

  How has Biomark Diagnostics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biomark Diagnostics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biomark Diagnostics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Biomark Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biomark Diagnostics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Biomark Diagnostics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biomark Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:20B Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.26 -1.05 1.26 0.03
2019-09-30 -0.53 0.46 0.05
2019-06-30 -0.56 0.47 0.07
2019-03-31 -0.55 0.47 0.06
2018-12-31 -0.57 0.47 0.07
2018-09-30 -0.60 0.47 0.06
2018-06-30 -0.65 0.53 0.05
2018-03-31 -0.73 0.60 0.06
2017-12-31 -0.82 0.67 0.08
2017-09-30 -0.75 0.66 0.07
2017-06-30 -0.68 0.60 0.06
2017-03-31 -0.72 0.64 0.05
2016-12-31 0.00 -1.18 1.15 -0.03
2016-09-30 0.00 -1.33 1.19 0.08
2016-06-30 -1.41 1.26 0.10
2016-03-31 -1.40 1.14 0.21
2015-12-31 0.00 -1.41 1.08 0.29
2015-09-30 0.00 -3.20 1.57 0.36
2015-06-30 -3.02 1.42 0.33
2015-03-31 -2.88 1.39 0.21
2014-03-31 -0.18 0.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biomark Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Biomark Diagnostics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biomark Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Biomark Diagnostics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biomark Diagnostics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

20B Health

 How is Biomark Diagnostics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biomark Diagnostics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biomark Diagnostics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Biomark Diagnostics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biomark Diagnostics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Biomark Diagnostics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biomark Diagnostics Company Filings, last reported 3 months ago.

DB:20B Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -0.33 0.95 0.72
2019-09-30 -1.00 0.00 0.07
2019-06-30 -0.89 0.00 0.16
2019-03-31 -1.22 0.00 0.02
2018-12-31 -1.10 1.01 0.06
2018-09-30 -1.01 0.89 0.03
2018-06-30 -0.85 0.86 0.13
2018-03-31 -0.90 0.00 0.04
2017-12-31 -0.80 0.70 0.12
2017-09-30 -0.63 0.66 0.28
2017-06-30 -0.66 0.78 0.46
2017-03-31 -1.07 0.00 0.02
2016-12-31 -0.84 0.00 0.00
2016-09-30 -0.75 0.55 0.01
2016-06-30 -0.60 0.43 0.00
2016-03-31 -0.55 0.00 0.01
2015-12-31 -0.51 0.34 0.00
2015-09-30 -0.26 0.22 0.02
2015-06-30 -0.09 0.14 0.04
2015-03-31 0.15 0.00 0.20
2014-03-31 0.09 0.00 0.09
  • Biomark Diagnostics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Biomark Diagnostics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Biomark Diagnostics has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Biomark Diagnostics has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -21.7% per year.
X
Financial health checks
We assess Biomark Diagnostics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biomark Diagnostics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

20B Dividends

 What is Biomark Diagnostics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biomark Diagnostics dividends.
If you bought €2,000 of Biomark Diagnostics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biomark Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biomark Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:20B Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biomark Diagnostics has not reported any payouts.
  • Unable to verify if Biomark Diagnostics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biomark Diagnostics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biomark Diagnostics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biomark Diagnostics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biomark Diagnostics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biomark Diagnostics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

20B Management

 What is the CEO of Biomark Diagnostics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rashid Bux
COMPENSATION CA$240,000
TENURE AS CEO 5.8 years
CEO Bio

Mr. Rashid Ahmed Bux, B.Sc., MBA, is the Founder of BioMark Technologies Inc., a bio pharm business, which has achieved Phase III status in an unprecedented 3 years and has been it Chief Executive Officer since June 19, 2014. Mr. Bux serves as Chief Executive Officer and President of Biomark Diagnostics Inc. He has more than 20 years of business management at the senior level. He was co-founder and Chief Operating Officer of Optima Health and KKT Spinecentres a developer and operator of spinal treatment centers located in Germany, China, Taiwan, UAE, Canada and India. He was President and Founder of Homeworks Inc. a subsidiary of BC Gas, the natural gas distributor in British Columbia, Canada. He servers on the board of two nternational health related companies and provides advisory services to African nations principally in East Africa. He has extensive contacts in the medical sectors on a global basis. He has been a Director of Biomark Diagnostics Inc. since June 19, 2014. He was inducted in the distinguished Phi Kappa Phi honorary for his outstanding educational achievement. He earned a Bachelor of Science in Business Administration with concentration in three areas from the Miami University in Ohio. He has the degree in Master of Business Administration from the University of Western Ontario where he earned several distinguished scholarships. He was a student at Nairobi University prior to obtaining a scholarship to attend Miami University.

CEO Compensation
  • Rashid's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Rashid's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Biomark Diagnostics management team in years:

2.8
Average Tenure
  • The tenure for the Biomark Diagnostics management team is about average.
Management Team

Rashid Bux

TITLE
Founder
COMPENSATION
CA$240K
TENURE
5.8 yrs

Gina Huang

TITLE
CFO & Project Director
TENURE
2.8 yrs

Thomas Malcolm

TITLE
Chief Scientific Officer

Neal Kaplan

TITLE
Chief Financial Officer of US

Daniel Sitar

TITLE
Principal Scientific Advisor

James Bond

TITLE
Chief of Surrey Hospital Thoracic Surgery Team
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure of the Biomark Diagnostics board of directors in years:

5.6
Average Tenure
  • The tenure for the Biomark Diagnostics board of directors is about average.
Board of Directors

Rashid Bux

TITLE
Founder
COMPENSATION
CA$240K
TENURE
5.8 yrs

Brian Cheng

TITLE
Independent Director
TENURE
5.6 yrs

Bram Ramjiawan

TITLE
Independent Director
TENURE
5.6 yrs

Bill Good

TITLE
Member of Media Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
22. Dec 19 Buy Guoyu Huang Individual 13. Dec 19 13. Dec 19 100,000 €0.20 €20,430
22. Dec 19 Buy Bux Investments Ltd. Company 13. Dec 19 13. Dec 19 100,000 €0.20 €20,430
15. Aug 19 Buy Grg Consulting Ltd. Company 13. Aug 19 13. Aug 19 3,000 €0.09 €277
26. Jun 19 Buy Grg Consulting Ltd. Company 26. Jun 19 26. Jun 19 5,000 €0.10 €490
21. Jun 19 Buy Grg Consulting Ltd. Company 18. Jun 19 18. Jun 19 500,000 €0.10 €49,998
21. Jun 19 Buy Bux Investments Ltd. Company 18. Jun 19 18. Jun 19 500,000 €0.10 €49,998
07. Jun 19 Buy Grg Consulting Ltd. Company 07. Jun 19 07. Jun 19 5,000 €0.07 €332
20. Apr 19 Buy Grg Consulting Ltd. Company 16. Apr 19 16. Apr 19 500,000 €0.07 €33,156
20. Apr 19 Buy Bux Investments Ltd. Company 16. Apr 19 16. Apr 19 370,000 €0.07 €24,536
X
Management checks
We assess Biomark Diagnostics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biomark Diagnostics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

20B News

Simply Wall St News

The Biomark Diagnostics (FRA:20B) Share Price Is Down 69% So Some Shareholders Are Wishing They Sold

Biomark Diagnostics Inc (FRA:20B) has rebounded strongly over the last week, with the share price soaring 140%. … Biomark Diagnostics hasn't yet reported any revenue yet, so it's as much a business idea as a business. … But with the share price diving 32% per year, over 3 years, it's probably fair to say that some shareholders no longer believe the company will succeed

Simply Wall St -

Biomark Diagnostics Inc (FRA:20B): How Does It Impact Your Portfolio?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … How 20B's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … However, this is the opposite to what 20B’s actual beta value suggests, which is higher stock volatility relative to the market.

Simply Wall St -

Should You Be Concerned About Biomark Diagnostics Inc's (FRA:20B) Shareholders?

This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: Institutional ownership in 20B is not at a level that would concern investors.

Simply Wall St -

Was Biomark Diagnostics Inc's (FRA:20B) Earnings Growth Better Than The Industry's?

When Biomark Diagnostics Inc's (DB:20B) announced its latest earnings (31 December 2017), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were Biomark Diagnostics's average earnings over the past couple of years, and its industry performance. … See our latest analysis for Biomark Diagnostics Did 20B's recent earnings growth beat the long-term trend and the industry?

Simply Wall St -

20B Company Info

Description

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a research collaboration with the University of Maryland School of Medicine related to the discovery and validation of biomarkers using a combinatorial technology approach. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Details
Name: Biomark Diagnostics Inc
20B
Exchange: DB
Founded: 2014
€7,086,745
72,313,729
Website: http://www.biomarkdiagnostics.com
Address: Biomark Diagnostics Inc
165–10551 Shellbridge Way,
Richmond,
British Columbia, V6X 2W8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB 20B Common Shares Deutsche Boerse AG DE EUR 26. Nov 2014
OTCPK BMKD.F Common Shares Pink Sheets LLC US USD 26. Nov 2014
CNSX BUX Common Shares Canadian National Stock Exchange CA CAD 26. Nov 2014
Number of employees
Current staff
Staff numbers
0
Biomark Diagnostics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:50
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2020/02/25
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.